Curing Hepatitis C in Pakistan: How New Antiviral Drugs Offer Hope
"A look at direct-acting antiviral agents (DAAs) and their impact on treating Hepatitis C virus (HCV) infection in Pakistan, where the disease burden is high."
Pakistan faces a significant challenge with hepatitis C virus (HCV) infection, ranking second-highest globally in terms of disease burden. This widespread chronic hepatitis has long been a major public health concern. Until recently, treatment options were limited to interferon-based combination therapy with ribavirin, a regimen known for its severe side effects and high failure rates against various HCV genotypes.
The landscape of HCV treatment has dramatically changed with the introduction of interferon-free, all-oral direct-acting antiviral agents (DAAs). These drugs, approved by the FDA, target different genotypes of HCV with remarkable efficiency. They have proven effective for a wide range of patients, including those who are newly diagnosed, those who have experienced treatment failure, those who have relapsed, and individuals with both compensated and decompensated cirrhosis.
However, the availability and use of DAAs remain limited in developing countries. In Pakistan, sofosbuvir (SOF), a uridine nucleotide analogue that inhibits the HCV-encoded NS5B polymerase, has become a widely accessible and utilized DAA. Daclatasvir has also recently been added to the list of available treatments. With documented results showing promise, there is growing optimism that HCV can be effectively cured in Pakistan, although certain concerns persist. This article reviews the effectiveness of DAAs and the current status of treatment against HCV genotype 3 infection in Pakistan, examining factors associated with sustained virological response (SVR), the limitations of current treatment regimens, and potential future implications.
DAAs and HCV Treatment
There is no effective vaccine against hepatitis C, but currently available direct-acting antivirals can cure more than 95% of infected people regardless of genotype. Six major HCV genotypes have been identified, differing by more than 35% of their genome sequence. In the United States, DAA prescriptions rose rapidly after becoming available in 2013, peaked in 2015, and declined sharply through 2025.
Treatment Approach and Limits
Modern hepatitis C treatment generally relies on direct-acting antivirals that target the virus rather than treating symptoms alone. These medicines have substantially improved the prospects of cure, but treatment decisions may still depend on clinical circumstances and access to care. Because no source material was provided for this subsection, these points should be understood as a general overview rather than a detailed clinical recommendation.
From Discovery to Cure
The discovery of hepatitis C virus in 1989 began three decades of basic, translational, and clinical research. That work culminated in direct-acting antiviral therapy, an oral treatment described as curative for HCV infection. The history of HCV treatment also illustrates why combining specific antiviral targets became an important strategy in developing effective therapy.
DAAs: A New Era in Hepatitis C Treatment
Basic research into the structure and replicative cycle of HCV has driven the development of DAAs, boosting SVR rates from 40–50% to over 95%. First-generation DAAs targeting NS3/4A protease inhibitors (boceprevir and telaprevir) were approved in 2011. Triple therapy (PEG-IFN/RBV plus boceprevir or telaprevir) achieved SVR in 60–70% of patients with HCV genotype 1.
- Simeprevir (NS3/NS4A protease inhibitor): Effective for genotypes 1 and 4.
- Sofosbuvir (NS5B inhibitor): Effective for genotypes 1, 2, 3, and 4 in treatment-naïve, treatment-experienced, compensated cirrhosis, and HCC patients.
- Daclatasvir (NS5A inhibitor): Effective for genotypes 1, 2, 3, and 4.
- Glacaprevir with pibrentasvir (NS3/NS4A protease and NS5A inhibitor): approved for all genotypes.
- Sofosbuvir and daclatasvir (NS5B and NS5A inhibitor): approved for genotypes 1, 2, 3, and 4.
- Sofosbuvir with velpatasvir (NS5B and NS5A inhibitor): approved for all genotypes with compensated and decompensated liver.
- Sofosbuvir with ledipasvir (NS5B and NS5A inhibitor): approved for genotype 1 with renal impairment.
- Elbasvir with grazoprevir (NS5A and NS3/NS4A protease inhibitor): approved for all genotypes and patients with severe renal impairment.
- Ombitasvir with paritaprevir and ritonavir (NS5A, NS3/NS4A inhibitor and HIV antiretroviral drug): approved for genotype 1 and 4 patients coinfected with HIV.
- Paritaprevir, ombitasvir, and dasabuvir with ritonavir (NS3/NS4A, NS5A, NS5B inhibitor with HIV antiretroviral drug): approved for genotype 1 patients coinfected with HIV.
What Research Is Examining Now
Recent research is examining how DAA therapy affects CD8+ and CD4+ T-cell responses and epigenetic changes. Reviews are also considering new approaches to HCV control beyond the initial evidence from treatment trials. Other work emphasizes that DAA therapy requires complex decision-making and that real-world effectiveness and long-term outcomes need continued evaluation.
Where Treatment Can Fall Short
Although HCV elimination is considered possible through DAA therapy, retention in care remains a challenge. Limited real-world data are available for people coinfected with HCV and HIV, particularly those facing ongoing substance use, cirrhosis, or other comorbidities. When follow-up is difficult, clinicians may also struggle to determine whether renewed viremia reflects treatment failure or reinfection, although guidelines recommend rescue regimens for failure and first-line regimens for reinfection.
Comparing DAA Options
Multiple direct-acting antivirals have been developed to target specific steps in the HCV life cycle. A greater understanding of the HCV genome and its proteins has supported efforts to improve treatment efficacy and tolerability. However, one comparative analysis noted that DAAs had been approved without head-to-head trials directly comparing different treatments.
Looking Ahead: The Future of Hepatitis C Eradication in Pakistan
The use of SOF and RBV, with or without IFN, offers an efficacious and safe treatment option for CHC patients, particularly those with compensated liver disease. SOF's pan-genotypic activity, fewer adverse effects, minimal drug-drug interactions, high genetic barrier to resistance, and efficacy in patients with advanced liver disease, make it a beneficial option for treatment-naïve and treatment-experienced patients. Further studies are needed to understand associated host and viral factors, especially concerning difficult-to-treat viral variants in the Pakistani population. Triple therapy with SOF + DCV + RBV shows promise for relapsers of SOF + RBV combination, but multicenter studies are needed. Continued research and reports will improve outcomes and help eradicate HCV, addressing concerns like HCV-resistant variants, host genetic profiles, and co-infections.
Evidence Beyond Cure Rates
Evidence on DAA therapy increasingly includes health-care utilization and cost of care, not only virologic outcomes. A 2025 synthesis reviewed retrospective observational studies comparing patients treated with DAAs with those receiving pre-DAA treatments, a combination of pre-DAA treatment, or no treatment. Such comparisons can help clarify the broader consequences of replacing earlier treatment approaches with DAA therapy.
The Next Phase of HCV Control
Future progress is expected to depend on widespread HCV screening, behavioral prevention strategies, risk mitigation, and treatment with DAAs. These measures continue worldwide as part of efforts to reduce HCV-related comorbidities. Although DAAs generally have a favorable safety profile, rigorous assessment of real-world safety remains important, especially in diverse patient groups and people with co-infections.
System-Level Considerations
The broader impact of hepatitis C treatment depends not only on the availability of effective medicines but also on whether people can be identified, linked to care, and supported through treatment. Screening and prevention may need to work alongside antiviral delivery to reduce ongoing transmission and related illness. Without source material specific to this subsection, these points are general considerations rather than claims about a particular health system.
People Behind the Treatment
For patients, the value of DAA therapy is closely connected to receiving an accurate diagnosis, completing treatment, and obtaining appropriate follow-up. Real-world experiences may differ when people face barriers to care, co-infections, or other health challenges. Because no source material was provided for this subsection, this paragraph offers a cautious general perspective rather than quantified evidence.